Ajay Major, MD, MBA
@majorajay.bsky.social
Lymphoma/CLL faculty at the University of Colorado School of Medicine. Patient-reported outcomes methodologist & #lymsm quality of life investigator. #medsky
Pinned
Check out all of this year's #MajorPROsASH, the top 20 best patient-reported outcomes & quality of life abstracts from #ASH24. 🧵 #ASHEducation #ASHKudos cc @ash-hematology.bsky.social
Announcing the MAGIC-ONC guidelines for the placement and management of vascular access devices in patients with cancer, including specific recommendations for both hematologic and solid tumor malignancies. #MAGICOnc #oncsky #medsky
www.acpjournals.org/doi/epdf/10.... cc @cuanschutz.bsky.social
www.acpjournals.org/doi/epdf/10.... cc @cuanschutz.bsky.social
November 4, 2025 at 10:47 PM
Announcing the MAGIC-ONC guidelines for the placement and management of vascular access devices in patients with cancer, including specific recommendations for both hematologic and solid tumor malignancies. #MAGICOnc #oncsky #medsky
www.acpjournals.org/doi/epdf/10.... cc @cuanschutz.bsky.social
www.acpjournals.org/doi/epdf/10.... cc @cuanschutz.bsky.social
Reposted by Ajay Major, MD, MBA
Finally out - our real world study of 740 patients with large B-cell lymphoma receiving polatuzumab vedotin shows higher response rates and PFS for patients with non-GCB LBCL than those with GCB disease, by Hans algorithm.
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
November 4, 2025 at 9:53 AM
Finally out - our real world study of 740 patients with large B-cell lymphoma receiving polatuzumab vedotin shows higher response rates and PFS for patients with non-GCB LBCL than those with GCB disease, by Hans algorithm.
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Reposted by Ajay Major, MD, MBA
An important step forward in improving vascular access safety for patients with cancer, introducing the MAGIC-ONC guidelines!
www.acpjournals.org/doi/epdf/10....
www.acpjournals.org/doi/epdf/10....
November 4, 2025 at 5:36 AM
An important step forward in improving vascular access safety for patients with cancer, introducing the MAGIC-ONC guidelines!
www.acpjournals.org/doi/epdf/10....
www.acpjournals.org/doi/epdf/10....
Reposted by Ajay Major, MD, MBA
Woah! @majorajay.bsky.social thinking through just about every hematology/oncology vascular access question possible (1422 scenarios, to be exact) to guide access choice. #medsky #oncsky #nursesky
Just a few examples below:
Just a few examples below:
November 4, 2025 at 4:28 AM
Woah! @majorajay.bsky.social thinking through just about every hematology/oncology vascular access question possible (1422 scenarios, to be exact) to guide access choice. #medsky #oncsky #nursesky
Just a few examples below:
Just a few examples below:
Late night publication (finally!) of our MAGIC-ONC appropriateness guidelines for vascular access in patients with cancer, now in @annalsofim.bsky.social. More to come tomorrow! #medsky #oncsky www.acpjournals.org/doi/full/10....
November 4, 2025 at 2:16 AM
Late night publication (finally!) of our MAGIC-ONC appropriateness guidelines for vascular access in patients with cancer, now in @annalsofim.bsky.social. More to come tomorrow! #medsky #oncsky www.acpjournals.org/doi/full/10....
Dr. Valerie Crabtree @stjude.bsky.social presented the findings of our qualitative study of patient and care partner perspectives in NLPHL at @worldsiop.bsky.social #SIOPCongress. Read our study here: pubmed.ncbi.nlm.nih.gov/40059593/ #lymsm cc @cucancercenter.bsky.social @cuanschutz.bsky.social
October 30, 2025 at 8:26 PM
Dr. Valerie Crabtree @stjude.bsky.social presented the findings of our qualitative study of patient and care partner perspectives in NLPHL at @worldsiop.bsky.social #SIOPCongress. Read our study here: pubmed.ncbi.nlm.nih.gov/40059593/ #lymsm cc @cucancercenter.bsky.social @cuanschutz.bsky.social
This morning's meeting of our monthly @accordsresearch.bsky.social imPROve Patient-Reported Outcomes Working Group. Phenomenal group of @cuanschutz.bsky.social @cucancercenter.bsky.social investigators working on new quality of life studies. #HRQoL medschool.cuanschutz.edu/accords/rese...
October 28, 2025 at 3:40 PM
This morning's meeting of our monthly @accordsresearch.bsky.social imPROve Patient-Reported Outcomes Working Group. Phenomenal group of @cuanschutz.bsky.social @cucancercenter.bsky.social investigators working on new quality of life studies. #HRQoL medschool.cuanschutz.edu/accords/rese...
RW pola outcomes by Hans COO @eddiecliff.bsky.social
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
October 27, 2025 at 4:30 PM
RW pola outcomes by Hans COO @eddiecliff.bsky.social
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
The first report of quality of life in patients with NLPHL from our ongoing NLPHLPRO multicenter trial (NCT06098430), presented by Dr. Jones at #ISCAYAHL.
Long-term survivors (most who received chemo) have low symptom burden and high global QOL & functioning. #lymsm cc @cuhematology.bsky.social
Long-term survivors (most who received chemo) have low symptom burden and high global QOL & functioning. #lymsm cc @cuhematology.bsky.social
October 23, 2025 at 8:05 PM
The first report of quality of life in patients with NLPHL from our ongoing NLPHLPRO multicenter trial (NCT06098430), presented by Dr. Jones at #ISCAYAHL.
Long-term survivors (most who received chemo) have low symptom burden and high global QOL & functioning. #lymsm cc @cuhematology.bsky.social
Long-term survivors (most who received chemo) have low symptom burden and high global QOL & functioning. #lymsm cc @cuhematology.bsky.social
Interested in adding PROs to your study, or developing a quality of life project?
Come to our imPROve Working Group @accordsresearch.bsky.social to get feedback from PRO researchers across @childrenscolo.bsky.social @cuanschutz.bsky.social. #oncsky
medschool.cuanschutz.edu/accords/rese...
Come to our imPROve Working Group @accordsresearch.bsky.social to get feedback from PRO researchers across @childrenscolo.bsky.social @cuanschutz.bsky.social. #oncsky
medschool.cuanschutz.edu/accords/rese...
October 20, 2025 at 5:06 PM
Interested in adding PROs to your study, or developing a quality of life project?
Come to our imPROve Working Group @accordsresearch.bsky.social to get feedback from PRO researchers across @childrenscolo.bsky.social @cuanschutz.bsky.social. #oncsky
medschool.cuanschutz.edu/accords/rese...
Come to our imPROve Working Group @accordsresearch.bsky.social to get feedback from PRO researchers across @childrenscolo.bsky.social @cuanschutz.bsky.social. #oncsky
medschool.cuanschutz.edu/accords/rese...
CAR-T in PCNSL #lymsm
- 67 pts, 25% CSF+, 12% eye+
- 57% axicel, 30% tisacel
- 58% CR, 1-yr PFS 50%, OS 66%
- 2-yr RFS better if CR/PR at CAR infusion: 56% vs 28%
- 27% G3+ ICANS!
Almost all got bridging; would love to know which agents.
academic.oup.com/neuro-oncolo...
- 67 pts, 25% CSF+, 12% eye+
- 57% axicel, 30% tisacel
- 58% CR, 1-yr PFS 50%, OS 66%
- 2-yr RFS better if CR/PR at CAR infusion: 56% vs 28%
- 27% G3+ ICANS!
Almost all got bridging; would love to know which agents.
academic.oup.com/neuro-oncolo...
P14.07.B CAR T-CELL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS: A MULTICENTER RETROSPECTIVE STUDY FROM THE LOC NETWORK
AbstractBACKGROUND. The use of CAR T-cell therapy has been delayed in primary central nervous system lymphomas (PCNSL) due to the fear of unacceptable neur
academic.oup.com
October 20, 2025 at 2:01 PM
CAR-T in PCNSL #lymsm
- 67 pts, 25% CSF+, 12% eye+
- 57% axicel, 30% tisacel
- 58% CR, 1-yr PFS 50%, OS 66%
- 2-yr RFS better if CR/PR at CAR infusion: 56% vs 28%
- 27% G3+ ICANS!
Almost all got bridging; would love to know which agents.
academic.oup.com/neuro-oncolo...
- 67 pts, 25% CSF+, 12% eye+
- 57% axicel, 30% tisacel
- 58% CR, 1-yr PFS 50%, OS 66%
- 2-yr RFS better if CR/PR at CAR infusion: 56% vs 28%
- 27% G3+ ICANS!
Almost all got bridging; would love to know which agents.
academic.oup.com/neuro-oncolo...
Patient- vs clinician-reported AEs from POLARIX @bloodjournals.hematology.org:
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...
October 14, 2025 at 7:58 PM
Patient- vs clinician-reported AEs from POLARIX @bloodjournals.hematology.org:
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...
CNS penetration of pola @bloodadvances.bsky.social
- 3 pts (1 PCNSL, 2 SCNSL): 2 had CR (although these pts received IT chemo & ibrutinib, respectively)
- pola detected in CSF of CNSL & systemic LBCL pts
Provocative but unclear about single-agent activity. #lymsm
ashpublications.org/bloodadvance...
- 3 pts (1 PCNSL, 2 SCNSL): 2 had CR (although these pts received IT chemo & ibrutinib, respectively)
- pola detected in CSF of CNSL & systemic LBCL pts
Provocative but unclear about single-agent activity. #lymsm
ashpublications.org/bloodadvance...
October 9, 2025 at 9:46 PM
CNS penetration of pola @bloodadvances.bsky.social
- 3 pts (1 PCNSL, 2 SCNSL): 2 had CR (although these pts received IT chemo & ibrutinib, respectively)
- pola detected in CSF of CNSL & systemic LBCL pts
Provocative but unclear about single-agent activity. #lymsm
ashpublications.org/bloodadvance...
- 3 pts (1 PCNSL, 2 SCNSL): 2 had CR (although these pts received IT chemo & ibrutinib, respectively)
- pola detected in CSF of CNSL & systemic LBCL pts
Provocative but unclear about single-agent activity. #lymsm
ashpublications.org/bloodadvance...
Happy ASH abstract notification day! Looking forward to all your posters and orals in just a few months. #ASH25 @ash.hematology.org
October 2, 2025 at 4:43 PM
Happy ASH abstract notification day! Looking forward to all your posters and orals in just a few months. #ASH25 @ash.hematology.org
Childhood cancer survivors face higher mortality after colorectal secondary cancers, with 50% diagnosed before age 40. Our new JNCI manuscript highlights need for tailored screening guidelines. #medsky #oncsky #survonc academic.oup.com/jnci/advance...
August 24, 2025 at 5:43 PM
Childhood cancer survivors face higher mortality after colorectal secondary cancers, with 50% diagnosed before age 40. Our new JNCI manuscript highlights need for tailored screening guidelines. #medsky #oncsky #survonc academic.oup.com/jnci/advance...
Survival after incidental vs symptomatic FL:
- 908 pts, 29% incidental
- incidental: more early stage & normal LDH
- no diff in EFS, lymphoma-specific survival, or OS between groups
We can answer the "what if this was picked up earlier" question! #lymsm
www.nature.com/articles/s41...
- 908 pts, 29% incidental
- incidental: more early stage & normal LDH
- no diff in EFS, lymphoma-specific survival, or OS between groups
We can answer the "what if this was picked up earlier" question! #lymsm
www.nature.com/articles/s41...
August 17, 2025 at 8:45 PM
Survival after incidental vs symptomatic FL:
- 908 pts, 29% incidental
- incidental: more early stage & normal LDH
- no diff in EFS, lymphoma-specific survival, or OS between groups
We can answer the "what if this was picked up earlier" question! #lymsm
www.nature.com/articles/s41...
- 908 pts, 29% incidental
- incidental: more early stage & normal LDH
- no diff in EFS, lymphoma-specific survival, or OS between groups
We can answer the "what if this was picked up earlier" question! #lymsm
www.nature.com/articles/s41...
Is this my brand now, ASH?! Very honored to receive this award! 🤣😂 #ASHCRTI @ash.hematology.org
August 8, 2025 at 10:06 PM
Is this my brand now, ASH?! Very honored to receive this award! 🤣😂 #ASHCRTI @ash.hematology.org
Dr. Susie Curtis: "Grants are like blood clots; you're more likely to get one if you've already had one." #medsky #ASHCRTI @ash.hematology.org
August 6, 2025 at 5:41 PM
Dr. Susie Curtis: "Grants are like blood clots; you're more likely to get one if you've already had one." #medsky #ASHCRTI @ash.hematology.org
Our CRTI group PROs and Poop! 💩 (intersection of patient-reported outcomes and fecal microbiome) #ASHCRTI cc @ash.hematology.org @biostatgirl.bsky.social
August 5, 2025 at 10:45 PM
Our CRTI group PROs and Poop! 💩 (intersection of patient-reported outcomes and fecal microbiome) #ASHCRTI cc @ash.hematology.org @biostatgirl.bsky.social
Day 1 of @ash.hematology.org CRTI! Super excited to learn from all these phenomenal investigators and faculty this week. #medsky #ASHKudos
August 3, 2025 at 3:08 PM
Day 1 of @ash.hematology.org CRTI! Super excited to learn from all these phenomenal investigators and faculty this week. #medsky #ASHKudos
Congratulations to Dr. Ogamba and this phenomenal group of investigators on execution of this large patient-reported outcomes study! And many thanks for the opportunity to contribute our PRO & financial toxicity methodologic expertise. #gyncsm #gynonc #medsky #oncsky
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Factors associated with health-related quality of life and financial toxicity among gynecological cancer patients in Southern Nigeria - Scientific Reports
Scientific Reports - Factors associated with health-related quality of life and financial toxicity among gynecological cancer patients in Southern Nigeria
www.nature.com
August 2, 2025 at 4:21 PM
Congratulations to Dr. Ogamba and this phenomenal group of investigators on execution of this large patient-reported outcomes study! And many thanks for the opportunity to contribute our PRO & financial toxicity methodologic expertise. #gyncsm #gynonc #medsky #oncsky
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Bispecifics in R/R LBCL @bloodjournals.hematology.org:
- 245 pts, 64% epcor, 60% CAR
- mPFS 2.5 mos (!!!): 2.3 epcor, 3.8 glofi
- mOS 7.8 mos overall (in MV model, glofi = better OS)
- worse PFS/OS if trial ineligible & w/i 90 d of CAR
Outcomes not great. #lymsm
ashpublications.org/blood/articl...
- 245 pts, 64% epcor, 60% CAR
- mPFS 2.5 mos (!!!): 2.3 epcor, 3.8 glofi
- mOS 7.8 mos overall (in MV model, glofi = better OS)
- worse PFS/OS if trial ineligible & w/i 90 d of CAR
Outcomes not great. #lymsm
ashpublications.org/blood/articl...
July 21, 2025 at 6:32 PM
Bispecifics in R/R LBCL @bloodjournals.hematology.org:
- 245 pts, 64% epcor, 60% CAR
- mPFS 2.5 mos (!!!): 2.3 epcor, 3.8 glofi
- mOS 7.8 mos overall (in MV model, glofi = better OS)
- worse PFS/OS if trial ineligible & w/i 90 d of CAR
Outcomes not great. #lymsm
ashpublications.org/blood/articl...
- 245 pts, 64% epcor, 60% CAR
- mPFS 2.5 mos (!!!): 2.3 epcor, 3.8 glofi
- mOS 7.8 mos overall (in MV model, glofi = better OS)
- worse PFS/OS if trial ineligible & w/i 90 d of CAR
Outcomes not great. #lymsm
ashpublications.org/blood/articl...
No more REMS for FDA-approved CAR-T products! Also, labeling updated for only 2 weeks in proximity to CAR center and 2 weeks no driving. #lymsm #tcellrx #mmsm www.fda.gov/vaccines-blo...
June 27, 2025 at 10:18 PM
No more REMS for FDA-approved CAR-T products! Also, labeling updated for only 2 weeks in proximity to CAR center and 2 weeks no driving. #lymsm #tcellrx #mmsm www.fda.gov/vaccines-blo...
